174 related articles for article (PubMed ID: 37943631)
1. PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.
Hu J; Hameed MR; Agaram NP; Whiting KA; Qin LX; Villano AM; O'Connor RB; Rozenberg JM; Cohen S; Prendergast K; Kryeziu S; White RL; Posner MC; Socci ND; Gounder MM; Singer S; Crago AM
Clin Cancer Res; 2024 Jan; 30(2):450-461. PubMed ID: 37943631
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract][Full Text] [Related]
3. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
Lazar AJ; Tuvin D; Hajibashi S; Habeeb S; Bolshakov S; Mayordomo-Aranda E; Warneke CL; Lopez-Terrada D; Pollock RE; Lev D
Am J Pathol; 2008 Nov; 173(5):1518-27. PubMed ID: 18832571
[TBL] [Abstract][Full Text] [Related]
4. Targeting stem cell behavior in desmoid tumors (aggressive fibromatosis) by inhibiting hedgehog signaling.
Ghanbari-Azarnier R; Sato S; Wei Q; Al-Jazrawe M; Alman BA
Neoplasia; 2013 Jul; 15(7):712-9. PubMed ID: 23814483
[TBL] [Abstract][Full Text] [Related]
5. β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis.
Huss S; Nehles J; Binot E; Wardelmann E; Mittler J; Kleine MA; Künstlinger H; Hartmann W; Hohenberger P; Merkelbach-Bruse S; Buettner R; Schildhaus HU
Histopathology; 2013 Jan; 62(2):294-304. PubMed ID: 23020601
[TBL] [Abstract][Full Text] [Related]
6. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.
McLean TD; Duchi S; Di Bella C
Target Oncol; 2022 May; 17(3):223-252. PubMed ID: 35446005
[TBL] [Abstract][Full Text] [Related]
8. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
[TBL] [Abstract][Full Text] [Related]
9. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
[TBL] [Abstract][Full Text] [Related]
10. A Metabolomics Pilot Study on Desmoid Tumors and Novel Drug Candidates.
Mercier KA; Al-Jazrawe M; Poon R; Acuff Z; Alman B
Sci Rep; 2018 Jan; 8(1):584. PubMed ID: 29330550
[TBL] [Abstract][Full Text] [Related]
11. TGF-β and CTGF are Mitogenic Output Mediators of Wnt/β-Catenin Signaling in Desmoid Fibromatosis.
Varghese S; Braggio DA; Gillespie J; Toland AE; Pollock R; Mayerson J; Scharschmidt T; Iwenofu OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):559-565. PubMed ID: 26894649
[TBL] [Abstract][Full Text] [Related]
12. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
[TBL] [Abstract][Full Text] [Related]
13. Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours.
Kattentidt Mouravieva AA; Geurts-Giele IR; de Krijger RR; van Noesel MM; van de Ven CP; van den Ouweland AM; Kromosoeto JN; Dinjens WN; Dubbink HJ; Smits R; Wagner A
Eur J Cancer; 2012 Aug; 48(12):1867-74. PubMed ID: 22305464
[TBL] [Abstract][Full Text] [Related]
14. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
[TBL] [Abstract][Full Text] [Related]
15. Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study.
Kwon J; Lee JH; Lee YH; Lee J; Ahn JH; Kim SH; Kim SH; Kim TI; Yun KH; Park YS; Kim JE; Lee KS; Choi JK; Kim HS
Cancer Res Treat; 2022 Oct; 54(4):1240-1255. PubMed ID: 35038826
[TBL] [Abstract][Full Text] [Related]
16. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.
Nathenson MJ; Hu J; Ratan R; Somaiah N; Hsu R; DeMaria PJ; Catoe HW; Pang A; Subhawong TK; Amini B; Sweet K; Feister K; Malik K; Jagannathan J; Braschi-Amirfarzan M; Sheren J; Caldas Y; Moreno Tellez C; Rosenberg AE; Lazar AJ; Maki RG; Benedetto P; Cohen J; Trent JC; Ravi V; Patel S; Wilky BA
Clin Cancer Res; 2022 Sep; 28(18):4092-4104. PubMed ID: 35180772
[TBL] [Abstract][Full Text] [Related]
17. Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors.
Matono H; Oda Y; Nakamori M; Tamiya S; Yamamoto H; Yokoyama R; Saito T; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2008 Dec; 39(12):1802-8. PubMed ID: 18715618
[TBL] [Abstract][Full Text] [Related]
18. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors).
Lips DJ; Barker N; Clevers H; Hennipman A
Eur J Surg Oncol; 2009 Jan; 35(1):3-10. PubMed ID: 18722078
[TBL] [Abstract][Full Text] [Related]
19. Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.
Braggio D; Koller D; Jin F; Siva N; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Strohecker AM; Lev D; Pollock RE
Cancer; 2019 Aug; 125(15):2693-2703. PubMed ID: 30980399
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors.
Braggio DA; Costas C de Faria F; Koller D; Jin F; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Horrigan SK; Han R; Larson JL; Strohecker AM; Pollock RE
PLoS One; 2022; 17(10):e0276047. PubMed ID: 36240209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
